FDA accepts Pfizer’s new CRC drug application & more: 3 GI industry key notes

Here are three updates from gastroenterology companies and practices from the past week:

Advertisement

The FDA accepted Pfizer’s supplemental New Drug Application for its combination therapy for advanced BRAF-mutant metastatic colorectal cancer and granted it priority review designation.

Check-Cap reported final results from its U.S. pilot study of its C-Scan System, a preparation-free colorectal cancer detection system.

Hattiesburg, Miss.-based Forrest General Hospital added Porter Glover, MD, Telciane Vesa, MD, and Andrew Weeks, MD, to its gastroenterology care team.

More articles on surgery centers:
Robotics might not be worth the ‘tremendous’ investment for ASCs — 2 leaders explain why
12 ASCs adding total joint replacements in 2019
Crystal Clinic Orthopedic Center celebrates northeast Ohio opening

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.